154 related articles for article (PubMed ID: 22535574)
21. Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?
Ngu H; Takiar R; Phillips T; Okosun J; Sehn LH
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35594501
[TBL] [Abstract][Full Text] [Related]
22. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.
Kim KM; Kim HC; Jeon KN; Kim HG; Kang JH; Hahm JR; Lee GW
Yonsei Med J; 2008 Feb; 49(1):155-8. PubMed ID: 18306483
[TBL] [Abstract][Full Text] [Related]
23. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.
Samaniego F; Hagemeister F; Romaguera JE; Fanale MA; Pro B; McLaughlin P; Rodriguez MA; Neelapu SS; Fayad L; Younes A; Feng L; Berkova Z; Khashab T; Sehgal L; Vega-Vasquez F; Kwak LW
Br J Haematol; 2015 Jun; 169(6):814-23. PubMed ID: 25828695
[TBL] [Abstract][Full Text] [Related]
24. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy.
Kusano Y; Yokoyama M; Terui Y; Inoue N; Takahashi A; Yamauchi H; Tsuyama N; Nishimura N; Mishima Y; Takeuchi K; Hatake K
Blood Cancer J; 2017 Sep; 7(9):e614. PubMed ID: 28960192
[No Abstract] [Full Text] [Related]
25. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Howard DS; Liesveld J; Phillips GL; Hayslip J; Weiss H; Jordan CT; Guzman ML
Leuk Res; 2013 Nov; 37(11):1502-8. PubMed ID: 24075534
[TBL] [Abstract][Full Text] [Related]
26. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Nastoupil LJ; Hess G; Pavlovsky MA; Danielewicz I; Freeman J; García-Sancho AM; Glazunova V; Grigg A; Hou JZ; Janssens A; Kim SJ; Masliak Z; McKay P; Merli F; Munakata W; Nagai H; Özcan M; Preis M; Wang T; Rowe M; Tamegnon M; Qin R; Henninger T; Curtis M; Caces DB; Thieblemont C; Salles G
Blood Adv; 2023 Nov; 7(22):7141-7150. PubMed ID: 37722354
[TBL] [Abstract][Full Text] [Related]
27. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
[TBL] [Abstract][Full Text] [Related]
28. Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.
Burack WR; Li H; Adlowitz D; Spence JM; Rimsza LM; Shadman M; Spier CM; Kaminski MS; Leonard JP; Leblanc ML; Smith SM; Friedberg JW
Blood Adv; 2023 Sep; 7(17):5082-5090. PubMed ID: 37379264
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.
Dudek AZ; Lesniewski-Kmak K; Shehadeh NJ; Pandey ON; Franklin M; Kratzke RA; Greeno EW; Kumar P
Br J Cancer; 2009 May; 100(9):1379-84. PubMed ID: 19401697
[TBL] [Abstract][Full Text] [Related]
30. Pixantrone beyond monotherapy: a review.
Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
[TBL] [Abstract][Full Text] [Related]
31. Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.
Ternant D; Cartron G; Hénin E; Tod M; Girard P; Paintaud G
Br J Clin Pharmacol; 2012 Apr; 73(4):597-605. PubMed ID: 21999172
[TBL] [Abstract][Full Text] [Related]
32. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Karmali R; Galvez C; Hamadani M; Gordon L; Winter J; Ma S; Nelson V; Fenske TS; Shah NN; Jagadeesh D; Klein A; Helenowski I; Chen R; Mi X; Petrich A; Evens AM; Pro B
Blood Adv; 2024 Apr; 8(7):1612-1620. PubMed ID: 38237077
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Schenk E; Hendrickson AE; Northfelt D; Toft DO; Ames MM; Menefee M; Satele D; Qin R; Erlichman C
Invest New Drugs; 2013 Oct; 31(5):1251-6. PubMed ID: 23543109
[TBL] [Abstract][Full Text] [Related]
34. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Leslie LA
Curr Treat Options Oncol; 2021 Oct; 22(12):111. PubMed ID: 34694508
[TBL] [Abstract][Full Text] [Related]
35.
Bascuas T; Moreno M; Grille S; Chabalgoity JA
Front Immunol; 2018; 9():7. PubMed ID: 29410666
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Kameoka Y; Takayama N; Hanamura I; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K; Nagai H
Cancer Sci; 2023 Aug; 114(8):3461-3465. PubMed ID: 37232264
[TBL] [Abstract][Full Text] [Related]
37. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Grant BW; Jung SH; Johnson JL; Kostakoglu L; Hsi E; Byrd JC; Jones J; Leonard JP; Martin SE; Cheson BD
Cancer; 2013 Nov; 119(21):3797-804. PubMed ID: 23922187
[TBL] [Abstract][Full Text] [Related]
39. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
Pedersen MA; Gormsen LC; Jakobsen LH; Eyre TA; Severinsen MT; Baech J; Dann EJ; Knapp A; Sahin D; Vestergaard P; El-Galaly TC; Jensen P
Br J Haematol; 2024 Apr; 204(4):1271-1278. PubMed ID: 37957542
[TBL] [Abstract][Full Text] [Related]
40. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
